Preparation and characterization of poly(lactic-co-glycolic acid) microspheres loaded with a labile antiparkinson prodrug.
暂无分享,去创建一个
C. van Nostrum | W. Hennink | A. D. Stefano | M. V. van Steenbergen | J. Siepmann | F. Siepmann | W E Hennink | A. Di Stefano | F Siepmann | J Siepmann | C. F. Nostrum | E D'Aurizio | C F van Nostrum | M J van Steenbergen | P Sozio | A Di Stefano | M. J. Steenbergen | P. Sozio | E. D'Aurizio | Jürgen Siepmann | J. Siepmann | Eleonora D'Aurizio
[1] Motohiro Uo,et al. Microparticle formation and its mechanism in single and double emulsion solvent evaporation. , 2004, Journal of controlled release : official journal of the Controlled Release Society.
[2] J. Siepmann,et al. Non-degradable microparticles containing a hydrophilic and/or a lipophilic drug: preparation, characterization and drug release modeling. , 2003, Journal of controlled release : official journal of the Controlled Release Society.
[3] Kinam Park,et al. Issues in long-term protein delivery using biodegradable microparticles. , 2010, Journal of controlled release : official journal of the Controlled Release Society.
[4] K. Zhu,et al. Preparation and in vitro release behaviour of 5-fluorouracil-loaded microspheres based on poly (L-lactide) and its carbonate copolymers. , 2003, Journal of microencapsulation.
[5] R. Herrero-Vanrell,et al. Biodegradable ibuprofen-loaded PLGA microspheres for intraarticular administration. Effect of Labrafil addition on release in vitro. , 2004, International journal of pharmaceutics.
[6] R. Duvoisin,et al. History of parkinsonism. , 1987, Pharmacology & therapeutics.
[7] C. Demerlis,et al. Review of the oral toxicity of polyvinyl alcohol (PVA). , 2003, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.
[8] C. van Nostrum,et al. Preparation and characterization of protein loaded microspheres based on a hydroxylated aliphatic polyester, poly(lactic-co-hydroxymethyl glycolic acid). , 2009, Journal of controlled release : official journal of the Controlled Release Society.
[9] J. Kressler,et al. Tracking the urinary excretion of high molar mass poly(vinyl alcohol). , 2007, Journal of biomedical materials research. Part B, Applied biomaterials.
[10] W. Dauer,et al. Parkinson's Disease Mechanisms and Models , 2003, Neuron.
[11] R. A. Jain,et al. The manufacturing techniques of various drug loaded biodegradable poly(lactide-co-glycolide) (PLGA) devices. , 2000, Biomaterials.
[12] S. Fahn,et al. Levodopa in the treatment of Parkinson's disease: A consensus meeting viewpoint , 1999, Movement disorders : official journal of the Movement Disorder Society.
[13] R. Jalil,et al. Microencapsulation using poly (L-lactic acid) II: Preparative variables affecting microcapsule properties. , 1990, Journal of microencapsulation.
[14] R. Mehta,et al. Biodegradable Polyesters for Drug and Polypeptide Delivery , 1993 .
[15] G. Giorgioni,et al. Dimeric L-dopa derivatives as potential prodrugs. , 2001, Bioorganic & medicinal chemistry letters.
[16] S. Sahoo,et al. Residual polyvinyl alcohol associated with poly (D,L-lactide-co-glycolide) nanoparticles affects their physical properties and cellular uptake. , 2002, Journal of controlled release : official journal of the Controlled Release Society.
[17] L. Perioli,et al. Ketoprofen poly(lactide-co-glycolide) physical interaction , 2007, AAPS PharmSciTech.
[18] F. Blandini,et al. Protective and symptomatic strategies for therapy of Parkinson's disease. , 1999, Drugs of Today.
[19] A. Bindoli,et al. Biochemical and toxicological properties of the oxidation products of catecholamines. , 1992, Free radical biology & medicine.
[20] Aliasger K Salem,et al. Formulating poly(lactide-co-glycolide) particles for plasmid DNA delivery. , 2008, Journal of pharmaceutical sciences.
[21] T. Aminabhavi,et al. Ethyl acetate as a dispersing solvent in the production of poly(DL-lactide-co-glycolide) microspheres: effect of process parameters and polymer type , 2002, Journal of microencapsulation.
[22] R. Gurny,et al. In Vitro Extended-Release Properties of Drug-Loaded Poly(DL-Lactic Acid) Nanoparticles Produced by a Salting-Out Procedure , 1993, Pharmaceutical Research.
[23] J. Benoit,et al. Biocompatibility of implantable synthetic polymeric drug carriers: focus on brain biocompatibility. , 2003, Biomaterials.
[24] Chi-Hwa Wang,et al. Mathematical modeling and simulation of drug release from microspheres: Implications to drug delivery systems. , 2006, Advanced drug delivery reviews.
[25] Steven P Schwendeman,et al. Principles of encapsulating hydrophobic drugs in PLA/PLGA microparticles. , 2008, International journal of pharmaceutics.
[26] Y. Zhang,et al. A new class of inhibitors of peptide sorption and acylation in PLGA. , 2009, Journal of controlled release : official journal of the Controlled Release Society.
[27] A. Hisaka,et al. Hydrolysis and acyl migration of a catechol monoester of L-dopa: L-3-(3-hydroxy-4-pivaloyloxyphenyl)alanine. , 1990, Journal of pharmaceutical sciences.
[28] Wenlei Jiang,et al. Biodegradable poly(lactic-co-glycolic acid) microparticles for injectable delivery of vaccine antigens. , 2005, Advanced drug delivery reviews.
[29] W. Gibb,et al. Neuropathology of Parkinson's disease and related syndromes. , 1992, Neurologic clinics.
[30] Samuel M. Goldman,et al. EPIDEMIOLOGY OF PARKINSON'S DISEASE , 1996, Neurologic Clinics.
[31] Daniel W Pack,et al. Microspheres for controlled release drug delivery , 2004, Expert opinion on biological therapy.
[32] M. Shive,et al. Biodegradation and biocompatibility of PLA and PLGA microspheres , 1997 .
[33] J. Benoit,et al. Paclitaxel-loaded microparticles and implants for the treatment of brain cancer: preparation and physicochemical characterization. , 2006, International journal of pharmaceutics.
[34] L. Perioli,et al. Physicochemical characterization and release mechanism of a novel prednisone biodegradable microsphere formulation. , 2008, Journal of pharmaceutical sciences.
[35] J. Andersen. Iron dysregulation and Parkinson's disease. , 2005, Journal of Alzheimer's disease : JAD.
[36] K. Johnston,et al. Encapsulation of protein nanoparticles into uniform-sized microspheres formed in a spinning oil film , 2005, AAPS PharmSciTech.
[37] L. Packer,et al. Neuroprotection by the Metabolic Antioxidant α-Lipoic Acid , 1997 .
[38] J. Siepmann,et al. PLGA-based microparticles: elucidation of mechanisms and a new, simple mathematical model quantifying drug release. , 2002, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[39] A H V Schapira,et al. Levodopa in the treatment of Parkinson’s disease , 2009, European journal of neurology.
[40] M. Widlansky,et al. Lipoic acid as a potential therapy for chronic diseases associated with oxidative stress. , 2004, Current medicinal chemistry.
[41] Xin Sun,et al. NMR spectroscopic evaluation of the internal environment of PLGA microspheres. , 2008, Molecular pharmaceutics.
[42] E. Santucci,et al. L-dopa- and dopamine-(R)-alpha-lipoic acid conjugates as multifunctional codrugs with antioxidant properties. , 2006, Journal of medicinal chemistry.
[43] T. Burke,et al. The Acidic Microclimate in Poly(lactide-co-glycolide) Microspheres Stabilizes Camptothecins , 1999, Pharmaceutical Research.
[44] P. Riederer,et al. Iron‐Melanin Interaction and Lipid Peroxidation: Implications for Parkinson's Disease , 1991, Journal of neurochemistry.
[45] A. Mitra,et al. Effect of lactide/glycolide ratio on the in vitro release of ganciclovir and its lipophilic prodrug (GCV-monobutyrate) from PLGA microspheres. , 2007, International journal of pharmaceutics.